ENDORET PRGF®
Autologous Plasma Rich in Growth Factors for Multispecialty Clinical Use
ENDORET PRGF® is a proprietary autologous plasma-based regenerative system developed by BTI Biotechnology Institute, designed to deliver standardised, leukocyte-free plasma rich in growth factors for use across multiple medical and surgical specialties.
The system is engineered to ensure reproducibility, traceability, and biological consistency, addressing the variability commonly associated with conventional PRP preparations.
Biological rationale
ENDORET PRGF® is an autologous therapy derived from the patient’s own peripheral blood. The blood is processed to obtain a plasma fraction with well-defined biological characteristics, including a moderate and carefully controlled platelet concentration, complete absence of leukocytes and erythrocytes, and a high concentration of biologically active growth factors. In addition, the preparation is associated with reduced pro-inflammatory cytokine activity, contributing to a more favorable healing environment.
Upon activation, platelets release a range of key mediators involved in tissue repair and regeneration, such as platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), and fibroblast growth factor (FGF). Together, these factors play a central role in promoting cell proliferation and differentiation, stimulating angiogenesis, enhancing extracellular matrix synthesis, and modulating the inflammatory response, thereby supporting effective and physiologically balanced tissue healing.
System characteristics
ENDORET PRGF® differs from generic PRP systems through:
- Closed, sterile preparation process
- Standardised centrifugation and fractionation protocol
- Leukocyte-free formulation to minimise catabolic and inflammatory effects
- High batch-to-batch reproducibility
- Full traceability from blood collection to clinical application
- This enables clinicians to apply PRGF® in a predictable and protocol-driven manner.
Patient advantages of Rejoint
Use this space to promote the business, its products or its services. Help people become familiar with the business and its offerings, creating a sense of connection and trust. Focus on what makes the business unique and how users can benefit from choosing it.
Improved functionality
Significantly enhances limb function by restoring joint mobility.
Item Title
Decreases pain during movement, improving quality of life.
Item Title
As a bioabsorbable implant, RegJoint™ eliminates the need for removal surgeries.
Item Title
Describe the item here. Include important features, pricing and other relevant info.
Technology adaptability across specialties
A key advantage of ENDORET PRGF® lies in its protocol-driven adaptability, enabling clinicians to tailor both preparation and application according to the specific clinical indication. The system allows controlled modification of several parameters, including platelet concentration, activation timing, and the selection between liquid or fibrin-based formulations.
ENDORET PRGF® can be delivered in multiple formats—such as injectable solutions, fibrin membranes, or three-dimensional scaffolds—depending on the anatomical site, tissue type, and therapeutic objective. This versatility supports use across diverse clinical environments while maintaining biological consistency, full traceability, and high reproducibility, which are essential for predictable clinical outcomes.
Autologous and Biocompatible
As an autologous treatment, Endoret® (PRGF®) eliminates the risk of adverse reactions or incompatibility, promoting natural healing processes.
Reduced Inflammation and Pain
The formulation is free from leukocytes and inflammatory proteins, leading to decreased inflammation, pain, and tissue fibrosis.
Enhanced Healing
By stimulating cell proliferation and migration, it accelerates tissue regeneration, improving clinical outcomes.
Versatility
Allows for the preparation of specific formulations adapted to each tissue and clinical requirement, enhancing treatment efficacy.
Multispecialty clinical applications
ENDORET PRGF® is used as an adjunctive regenerative therapy across a wide range of disciplines, where tissue healing, inflammation control, and biological support are clinically relevant.
In orthopaedics and sports medicine, Endoret PRGF® is used as a biological adjunct to support tissue healing, modulate inflammation, and aid functional recovery following acute injury or degenerative musculoskeletal conditions. The leukocyte-free composition is particularly relevant in musculoskeletal applications, where excessive inflammatory mediators may contribute to catabolic tissue processes and prolonged post-treatment pain.
The technology is most adapted through liquid, activated PRGF® formulations, enabling targeted delivery via injection into joints, tendons, ligaments, muscles, or peri-tendinous structures. The absence of leukocytes helps to reduce post-injection inflammatory reactions, making it suitable for tendinopathies, ligament injuries, muscle lesions, and degenerative joint disease, including osteoarthritis.
For surgical applications, Endoret PRGF® can also be prepared in the form of a fibrin matrix or membrane, providing a biological scaffold that supports cell migration and the sustained local release of growth factors. This format is frequently used intra-operatively to support soft tissue healing, tendon repair, and post-surgical recovery.
In dermatology and aesthetic medicine, Endoret PRGF® is utilised to support skin regeneration, improve tissue quality, and stimulate hair follicle activity. Treatment protocols are adapted according to the anatomical site and therapeutic objective.
The system enables the preparation of fibrin-free, injectable PRGF®, which is particularly suitable for intradermal application where even diffusion and biological stimulation are required without volumising effects or excessive fibrosis. The release of growth factors supports fibroblast proliferation, collagen synthesis, angiogenesis, and overall dermal remodelling.
In hair restoration protocols, PRGF® is typically administered as a liquid injectable formulation, optimising the follicular microenvironment and supporting hair cycle regulation. The autologous and leukocyte-free nature of the product minimises inflammatory response, which is especially important in scalp treatments.
Where clinically indicated, PRGF® fibrin matrices may also be used to support wound healing and tissue recovery following dermatological surgery or aesthetic procedures.
Within reproductive medicine, ENDORET PRGF® is applied as a regenerative biological support therapy, particularly in protocols aimed at optimising tissue receptivity and endometrial conditions.
For these applications, the technology is adapted to produce a highly purified, fibrin-free liquid PRGF®, allowing precise intrauterine or targeted tissue application without clot formation. This formulation supports angiogenesis, cellular proliferation, and tissue remodelling while maintaining a controlled inflammatory profile.
The absence of leukocytes and exogenous additives is of particular importance in reproductive indications, where immunological balance and tissue compatibility are critical. PRGF® is used as an adjunct within defined clinical protocols and under specialist supervision.
Clinical Evidence and Regulatory Compliance
Explore the technical research and clinical studies below to learn more about the science behind Endoret® (PRGF®).